Dr Eric Berg, D.C., an established health educator and best-selling author, has publicly aligned with Robert F. Kennedy Jr. in a call for greater transparency and integrity in vaccine science and health policy. Widely recognised for his expertise in nutrition and holistic health, Dr Berg has raised concerns over weaknesses in vaccine safety testing--particularly the practice of using active vaccines as comparators instead of inert placebos--and the potential for conflicts of interest within major health authorities. By collaborating with Kennedy, a long-standing campaigner for corporate accountability, Dr Berg highlights a growing movement that is pushing for unbiased research, open discussion, and meaningful informed consent. Their joint aim is to give individuals the ability to make their own health decisions based on transparent, comprehensive data, while challenging the role of pharmaceutical interests in shaping public health institutions.
ALEXANDRIA, Va. – Dr Eric Berg, D.C., a respected health educator and best-selling author, today declared his strong alignment with Robert F. Kennedy Jr. in promoting transparency and scientific rigour within public health, especially in relation to vaccines and policy. Known for his work in nutrition and holistic medicine, Dr Berg stresses the importance of impartial research and open debate about vaccine safety, echoing Kennedy's criticism of pharmaceutical influence over health agencies.
Dr Berg's position follows his examination of vaccine science, where he identifies what he considers fundamental weaknesses in current safety trial methods. "The prevailing practice of comparing new vaccines against other active vaccines, rather than inert placebos, creates a misleading picture of safety," states Dr. Berg. "This approach can obscure potential adverse effects, particularly those linked to adjuvants like aluminum, which have been implicated in conditions such as Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)."
His concerns also extend to possible conflicts of interest within leading health institutions. Dr Berg highlights examples such as the Centres for Disease Control and Prevention (CDC) holding vaccine patents and receiving royalties, which he believes may compromise impartiality in their public health guidance.
Robert F. Kennedy Jr., an environmental lawyer and long-time public health advocate, has consistently challenged both the pharmaceutical industry and government policies. Dr Berg commends Kennedy's determination: "RFK Jr. has a proven track record of successfully challenging powerful corporations and fighting for the truth," Dr. Berg asserts. "His legal expertise and dedication to uncovering corruption are precisely what is needed to bring much-needed reform and integrity to our public health institutions."
The partnership between Dr Berg and Kennedy signals the rise of a movement demanding more transparent and honest conversations around medical interventions. Both stress that genuine informed consent--grounded in full and transparent scientific data--is essential if individuals are to make independent health choices.
Dr Berg Nutritionals continues to focus on equipping people with knowledge and resources to achieve health through natural and holistic methods. This collaboration with Robert F. Kennedy Jr. strengthens their shared commitment to question prevailing narratives and promote a health model built on scientific integrity and public well-being.
source:newsreleases.co.uk
LakeShore Biopharma receives Nasdaq delisting determination letter
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15
GC Biopharma files IND for Phase 3 trial of BARYCELA in Thailand
Novavax COVID-19 vaccine approved in US
WHO and UNICEF deploy PharmaJet's Tropis ID system in Afghanistan polio campaign
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process